TetraLogic Pharmaceuticals IPO Research Information

TetraLogic Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on TetraLogic Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
TetraLogic Pharmaceuticals	TLOG - NASDAQ	$7.00-$7.00	$7.00	$7.00	7.2 million	12/12/2013
Underwriter(s): Oppenheimer & Co., Guggenheim Securities, Needham & Co.
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2013-10-18

TetraLogic Pharmaceuticals Quote & Chart - Click for current quote - TLOG

About TetraLogic Pharmaceuticals (adapted from TetraLogic Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct.

This description is adapted from TetraLogic TLOG prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as TetraLogic TLOG "TLOG" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.